Literature DB >> 27081514

Osteogenesis imperfecta IIC caused by a novel heterozygous mutation in the C-propeptide region of COL1A1.

Masaki Takagi1, Mitsuru Matsushita2, Gen Nishimura3, Tomonobu Hasegawa4.   

Abstract

Osteogenesis imperfecta IIC (OI IIC), which is a rare variant of lethal OI that has been considered to be an autosomal recessive trait, is characterized by twisted, slender long bones with dense metaphyseal margins. Here, we report a typical case of OI IIC caused by a novel heterozygous mutation in the C-propeptide region of COL1A1. OI IIC seems to be caused by a dominant mutation of COL1A1.

Entities:  

Year:  2014        PMID: 27081514      PMCID: PMC4785516          DOI: 10.1038/hgv.2014.25

Source DB:  PubMed          Journal:  Hum Genome Var        ISSN: 2054-345X


  14 in total

1.  Heterozygous C-propeptide mutations in COL1A1: osteogenesis imperfecta type IIC and dense bone variant.

Authors:  Masaki Takagi; Naoaki Hori; Yasutsugu Chinen; Kenji Kurosawa; Yukichi Tanaka; Kikuko Oku; Hitomi Sakata; Ryuji Fukuzawa; Gen Nishimura; Jürgen Spranger; Tomonobu Hasegawa
Journal:  Am J Med Genet A       Date:  2011-08-10       Impact factor: 2.802

2.  Disruption of one intra-chain disulphide bond in the carboxyl-terminal propeptide of the proalpha1(I) chain of type I procollagen permits slow assembly and secretion of overmodified, but stable procollagen trimers and results in mild osteogenesis imperfecta.

Authors:  J M Pace; C D Kuslich; M C Willing; P H Byers
Journal:  J Med Genet       Date:  2001-07       Impact factor: 6.318

3.  Perinatal lethal osteogenesis imperfecta: radiologic and pathologic evaluation of seven prenatally diagnosed cases.

Authors:  H J van der Harten; J T Brons; P F Dijkstra; C J Meijer; H P van Geijn; N F Arts; M F Niermeijer
Journal:  Pediatr Pathol       Date:  1988

4.  A single amino acid substitution (D1441Y) in the carboxyl-terminal propeptide of the proalpha1(I) chain of type I collagen results in a lethal variant of osteogenesis imperfecta with features of dense bone diseases.

Authors:  J M Pace; D Chitayat; M Atkinson; W R Wilcox; U Schwarze; P H Byers
Journal:  J Med Genet       Date:  2002-01       Impact factor: 6.318

5.  Osteogenesis imperfecta: a pasture for splitters and lumpers.

Authors:  J Spranger
Journal:  Am J Med Genet       Date:  1984-02

6.  The effect of carboxyl-terminal propeptide of type I collagen (c-propeptide) on collagen synthesis of preosteoblasts and osteoblasts.

Authors:  M Mizuno; R Fujisawa; Y Kuboki
Journal:  Calcif Tissue Int       Date:  2000-11       Impact factor: 4.333

7.  Carboxyl-terminal propeptide of type I collagen (c-propeptide) modulates the action of TGF-beta on MC3T3-E1 osteoblastic cells.

Authors:  M Mizuno; R Fujisawa; Y Kuboki
Journal:  FEBS Lett       Date:  2000-08-18       Impact factor: 4.124

8.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

Review 9.  New genes in bone development: what's new in osteogenesis imperfecta.

Authors:  Joan C Marini; Angela R Blissett
Journal:  J Clin Endocrinol Metab       Date:  2013-06-14       Impact factor: 5.958

10.  Endoplasmic reticulum-mediated quality control of type I collagen production by cells from osteogenesis imperfecta patients with mutations in the pro alpha 1 (I) chain carboxyl-terminal propeptide which impair subunit assembly.

Authors:  S R Lamandé; S D Chessler; S B Golub; P H Byers; D Chan; W G Cole; D O Sillence; J F Bateman
Journal:  J Biol Chem       Date:  1995-04-14       Impact factor: 5.157

View more
  2 in total

1.  A novel COL1A1 mutation in a family with osteogenesis imperfecta associated with phenotypic variabilities.

Authors:  Toshiyuki Seto; Toshiyuki Yamamoto; Keiko Shimojima; Haruo Shintaku
Journal:  Hum Genome Var       Date:  2017-03-16

2.  COL1A2 p.Gly1066Val variant identified in a Han Chinese family with osteogenesis imperfecta type I.

Authors:  Mingyuan Wang; Yi Guo; Pengfei Rong; Hongbo Xu; Lina Gong; Hao Deng; Lamei Yuan
Journal:  Mol Genet Genomic Med       Date:  2019-03-04       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.